


Methyl 2,2,4,8-tetramethyl-6-oxo-2*H*,6*H*-  
pyrimidino[2,1-*b*]thiazine-7-carboxylateMichel Evain,<sup>a\*</sup> Cyrille  
Landreau,<sup>b</sup> David Deniaud,<sup>b</sup>  
Alain Reliquet<sup>b</sup> and Jean Claude  
Meslin<sup>b</sup><sup>a</sup>Institut des Matériaux Jean Rouxel, 2 rue de la  
Houssinière, BP 32229, 44322 Nantes Cedex 3,  
France, and <sup>b</sup>Laboratoire de Synthèse  
Organique, UMR CNRS 6513, Faculté des  
Sciences et des Techniques, 2 rue de la  
Houssinière, BP 92208, 44322 Nantes Cedex 3,  
France

Correspondence e-mail: evain@cnsr-immn.fr

## Key indicators

Single-crystal X-ray study  
*T* = 293 K  
Mean  $\sigma(\text{C}-\text{C}) = 0.004 \text{ \AA}$   
*R* factor = 0.045  
*wR* factor = 0.102  
Data-to-parameter ratio = 23.8For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.The title compound, C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S, contains a non-planar  
thiazine ring fused to a planar pyrimidine ring.Received 13 March 2002  
Accepted 19 March 2002  
Online 28 March 2002

## Comment

Despite the fact that pyrimido[2,1-*b*][1,3]thiazines are rather  
uncommon heterocycles, these compounds may be regarded  
as potentially biologically active candidates. A series of new  
3,4-dihydro-2*H*,6*H*-pyrimido[2,1-*b*][1,3]thiazines was there-  
fore evaluated by Bózsing *et al.* (1996) and these molecules  
proved to be promising anti-inflammatory and antipyretic  
agents.The main route to these bicyclic compounds involves the  
condensation of a 2-thioxopyrimidine with an appropriate  
dielectrophile, which entails, in certain cases, the formation of  
two regioisomers (Kappe & Roschger, 1989). Since then,  
several alternative routes have been proposed (*e.g.* Fülöp *et al.*,  
1991; Hanefeld *et al.*, 1996), most of these suffering from  
low versatility.Our continuing program in heterocyclic synthesis has led us  
to develop a regioselective methodology allowing the  
preparation of various 2*H*,6*H*-pyrimido[2,1-*b*][1,3]thiazine  
and 2*H*,6*H*-pyrimido[2,1-*b*][1,3]thiazin-6-one derivatives, such  
as the title compound, (I) (Landreau *et al.*, 2002). As part of  
these results, we report here the molecular structure of (I).All the atoms of the pyrimidine ring and some of the atoms  
of the thiazine ring are almost coplanar (with a maximum  
deviation of 0.136 Å for C6). Atoms C2 and C4 of the thiazine  
ring lie on opposite sides of this plane, at distances of 0.729 (2)  
and 0.350 (2) Å, respectively. The methyl ester group is tilted  
by 55.32 (11)° out of the plane.

## Experimental

A solution of *N,N*-dimethyl-*N'*-(4,6,6-trimethyl-6*H*-1,3-thiazin-2-yl)-  
acetamide (2 mmol) and methyl malonyl chloride (2.4 mmol) in  
dichloromethane (10 ml) was stirred at room temperature for 6 h.  
After cooling to 273 K, triethylamine (4.8 mmol) was added and  
stirring was continued at room temperature for 16 h. After removal  
of the solvent, the residue was chromatographed using CH<sub>2</sub>Cl<sub>2</sub>/  
EtOAc (9:1) as eluent. Crystallization from a solution in diethyl ether

gave (I) as white crystals (95%); m.p. 403 K. Single crystals suitable for X-ray analysis were obtained by slow evaporation at room temperature from diethyl ether.

#### Crystal data

$C_{13}H_{16}N_2O_3S$   
 $M_r = 280.3$   
 Monoclinic,  $P2_1/c$   
 $a = 12.399(5) \text{ \AA}$   
 $b = 12.8080(9) \text{ \AA}$   
 $c = 13.348(5) \text{ \AA}$   
 $\beta = 138.032(18)^\circ$   
 $V = 1417.5(9) \text{ \AA}^3$   
 $Z = 4$

$D_x = 1.313 \text{ Mg m}^{-3}$   
 Mo  $K\alpha$  radiation  
 Cell parameters from 25 reflections  
 $\theta = 9.2\text{--}16.8^\circ$   
 $\mu = 0.23 \text{ mm}^{-1}$   
 $T = 293 \text{ K}$   
 Block, colourless  
 $0.30 \times 0.15 \times 0.15 \text{ mm}$

#### Data collection

Nonius CAD-4 and Stoe IPDS diffractometers  
 $\theta/2\theta$  and  $\omega$  scans  
 Absorption correction: Gaussian (JANA2000; Petricek & Dusek, 2000)  
 $T_{\min} = 0.941$ ,  $T_{\max} = 0.966$   
 28 762 measured reflections  
 4119 independent reflections

2258 reflections with  $I > 2\sigma(I)$   
 $R_{\text{int}} = 0.079$   
 $\theta_{\text{max}} = 30.1^\circ$   
 $h = -17 \rightarrow 16$   
 $k = -17 \rightarrow 17$   
 $l = -17 \rightarrow 18$   
 3 standard reflections  
 frequency: 60 min  
 intensity decay: 0.7%


#### Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.045$   
 $wR(F^2) = 0.102$   
 $S = 1.07$   
 4119 reflections  
 173 parameters  
 H-atom parameters constrained  
 $w = 1/[\sigma^2(I) + 0.0016F^2]$

$(\Delta/\sigma)_{\text{max}} < 0.001$   
 $\Delta\rho_{\text{max}} = 0.49 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.42 \text{ e \AA}^{-3}$   
 Extinction correction: B—C type 1  
 Lorentzian isotropic (Becker & Coppens, 1974)  
 Extinction coefficient: 0.23 (4)

CAD-4 and IPDS data sets (8371 and 20391 reflections, respectively) were scaled on the basis of 3274 common reflections with  $I > 10\sigma(I)$  [scale factor: 0.1710 (3)]. The orientation of the  $\text{CH}_3$  groups were determined from difference Fourier syntheses and initially refined using rigid bodies. All H atoms were then fixed at calculated and/or refined positions. Riding isotropic displacement parameters were used for all H atoms.

Data collection: CAD-4-PC (Enraf–Nonius, 1993) and EXPOSE (Stoe & Cie, 1997); cell refinement: CELDIM (Enraf–Nonius, 1993); data reduction: JANA2000 (Petricek & Dusek, 2000); program(s) used to solve structure: SHELXTL (Sheldrick, 1995); program(s)



**Figure 1**

The molecular structure of (I), showing 50% probability displacement ellipsoids. H atoms have been omitted for clarity.

used to refine structure: JANA2000; molecular graphics: DIAMOND (Brandenburg & Berndt, 1999); software used to prepare material for publication: JANA2000.

The authors gratefully acknowledge financial support by the French Ministry of Education and CNRS.

#### References

- Becker, P. J. & Coppens, P. (1974). *Acta Cryst.* **A30**, 129–153.  
 Bózsing, D., Sohár, P., Gigler, G. & Kovács, G. (1996). *Eur. J. Med. Chem.* **31**, 663–668.  
 Brandenburg, K. & Berndt, M. (1999). *DIAMOND*. Crystal Impact GbR, Bonn, Germany.  
 Enraf–Nonius (1993). *CAD-4-PC*. Enraf–Nonius, Delft, The Netherlands.  
 Fülöp, F., Huber, I., Szabó, Á., Bernáth, G. & Sohár, P. (1991). *Tetrahedron*, **47**, 7673–7676.  
 Hanefeld, W., Naeeni, M. & Schlitzer, M. (1996). *J. Heterocycl. Chem.* **33**, 1903–1907.  
 Kappe, C. O. & Roschger, P. (1989). *J. Heterocycl. Chem.* **26**, 55–64.  
 Landreau, C., Deniaud, D., Reliquet, A. & Meslin, J. C. (2002). *Synthesis*, **3**, 403–408.  
 Petricek, V. & Dusek, M. (2000). *JANA2000*. Institute of Physics, Praha, Czech Republic.  
 Sheldrick, G. M. (1995). *SHELXTL*. Version 5.0. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.  
 Stoe & Cie (1997). *EXPOSE* and *CELL* in *Stoe IPDS*. Stoe & Cie GmbH, Darmstadt, Germany.